跳至主要内容
临床试验/NCT05498688
NCT05498688招募中不适用

The Acute Effect of a Low-carbohydrate Meal on the Plasma Fatty Acid Composition in Patients With Type 2 Diabetes

Odense University Hospital2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2022年8月25日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
12
试验地点
2
主要终点
Plasma fatty acid composition

研究概览

简要总结

The investigators wishes to investigate the acute effect of a low carbohydrate meal on the plasma fatty acid (FA) composition compared with a control meal in a cross-over study of patients with type 2 diabetes (T2D).

In two trial days 12 participants with T2D will either have a low carbohydrate meal or control meal, measurements will be performed at baseline and continuously over 5 hours.

详细描述

Type 2 diabetes (T2D) is the most common metabolic disorder worldwide, and with an increasing prevalence T2D has become a major healthcare burden.

Low carbohydrate diet (LCD) has become increasingly popular as a method of improving glycemic control in patients with type 2 diabetes. However, the higher content of especially saturated fat in LCD has raised concerns about harmful effects.

A previous study has shown increase in non esterified fatty acids after a low carbohydrate meal, but it still needs to be investigated how a low carbohydrate meal affects the plasma FA composition.

The aim of this project is to investigate the hypothesis that a single low carbohydrate meal results in an improved plasma FA composition in patients with T2D and that this, at least in part, corresponds to the changes observed after 6 months LCD.

The study will be conducted as a cross-over trial with 12 participants with T2D. The participants will randomly be assigned to either start with the low carbohydrate meal or a control meal with a 2 weeks washout period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Duration of established type 2 diabetes for more than six months and less than five years, but duration of type 2 diabetes for up to 10 years if the current treatment consists of ≤ 2 oral antidiabetic drugs without insulin.
  • HbA1c in compliance with type 2 diabetes (above 48 mmol/mol), with or without use of glucose-lowering pharmacotherapy, but without need for adjustment of antidiabetic treatment.
  • Stable antidiabetic treatment three months prior to inclusion.
  • Well treated dyslipidemia (LDL cholesterol < 2.5 mmol/l and total cholesterol < 4.5 mmol/l at inclusion) with or without statins.
  • Age ≥ 18 years.
  • All participants have to understand oral and written Danish.
  • All participants have to sign an informed consent after oral and written information on experimental design.

排除标准

  • Significant comorbidity, including liver disease.
  • A history of cancer < 5 years or current chemotherapy.
  • Other severe co-morbidity that could interfere with study compliance or safety (e.g. previous gastrointestinal operations, liver disease, history of eating disorder, current alcohol overuse or hypoglycemic unawareness).
  • Current treatment with glucocorticoids (systemic).
  • Continuous treatment with steatosis-inducing drugs.
  • Treatment with antibiotics during the last two months before inclusion.
  • Low-carbohydrate diet prior to inclusion, or other restrictive diet.
  • Weight-loss > 10 kg over the last three months before inclusion.
  • Pregnancy or expected pregnancy within the next 6 months.
  • Elevated blood pressure (180/110) with or without antihypertensives.

结局指标

主要结局

Plasma fatty acid composition

时间窗: 5 hours

Quantified as weight percentage (wt%) of total plasma phospholipid FA

次要结局

  • Subjective appetite(5 hours)
  • Plasma glucose(5 hours)
  • Serum insulin(5 hours)
  • Plasma free fatty acid(5 hours)
  • LDL cholesterol(5 hours)
  • Triglycerides(5 hours)
  • Glucagon Like Peptide 1 (GLP1)(5 hours)
  • HDL cholesterol(5 hours)
  • Glucose-Dependent Insulinotropic Polypeptide (GIP)(5 hours)
  • Peptide YY (PYY)(5 hours)
  • Plasma ketones(5 hours)
  • Total cholesterol(5 hours)
  • Other lipoprotein fractions(5 hours)
  • Cholecystokinin (CCK)(5 hours)
  • Ghrelin(5 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Karina Vejrum Sørensen

Nutrition consultant

Odense University Hospital

研究点 (2)

Loading locations...

相似试验